Filing Flows › Health Care › Regen BioPharma (RGBP)
Regen BioPharma (RGBP) earnings and revenue breakdown
Latest: Q3 FY26 · 10-Q filed Aug 17, 2026 · Regen BioPharma (RGBP) Q3 FY26 earnings results →
Q3 FY26 Revenue up 0% year over year to $59K · operating margin 41.5%
Regen BioPharma made $59K in Q3 FY26 (0% Y/Y). Operating margin 41.5%, net loss $638K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 17, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $59K in Q3 FY26, roughly flat year over year and roughly flat from the previous quarter.
Operating profit was $25K, a 41.5% margin (up 110.5 points year over year). Total costs fell 65% while revenue was flat. The quarter ended with a net loss of $638K, after a profit of $1.0M the previous quarter. Net interest and other expense of $662K was the main reason.
Operating cash flow was −$24K. Working capital and other items added $614K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 FY26 | 10-Q | Aug 17, 2026 | $59K | 0% | 41.5% | −$638K | −$24K |
| Q2 FY26 | 10-Q | May 14, 2026 | $59K | 0% | -260.2% | $992K | −$63K |
| Q1 FY26 | 10-Q | Feb 13, 2026 | $59K | 0% | -933.9% | −$968K | −$198K |
| Q3 FY25 | 10-Q | Aug 11, 2025 | $59K | 0% | -69.0% | −$167K | −$56K |
| Q2 FY25 | 10-Q | May 28, 2025 | $59K | 0% | -191.9% | −$19K | −$101K |
| Q4 FY24 | 10-K | May 13, 2025 | $59K | — | -143.9% | −$66K | −$207K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Regen BioPharma
We were incorporated April 24, 2012 under the laws of the State of Nevada. We intend to engage primarily in the development of regenerative medical applications which we intend to license, develop internally or acquire outright from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.
In its own words, from its 10-K, filed Dec 30, 2025.
Regen BioPharma against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 0% against the peers' median +7%. Operating margin: 41.5% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RGBP Regen BioPharma | Q3 FY26 | $59K | 0% | 41.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Regen BioPharma 10-Q on SEC EDGAR · CIK 1589150 · Pharmaceutical Preparations
More on RGBP
History
Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q3 FY25 results · Q2 FY25 results · Q4 FY24 results